LUNG Stock — Pulmonx Corp

Pulmonx Corp (LUNG)

Updated October 16, 2026.

LUNG is a Stock. Total return is -95.5% over the past 6 years, 241.0 points behind SPY at 145.5%.

Pulmonx Corporation is a commercial-stage medical technology company that develops minimally invasive treatments for patients with severe emphysema, a form of chronic obstructive pulmonary disease. Its core product is the Zephyr Endobronchial Valve system, supported by diagnostic tools including the Chartis Pulmonary Assessment System and the cloud-based LungTraX Platform for patient assessment and treatment planning. The company does not currently distribute to shareholders.

LUNG performance versus SPY

Price and return data through 2026-10-16.

Total return is -95.5% over the past 6 years, 241.0 points behind SPY at 145.5%. Over the past year its total return — price change plus distributions reinvested — is 13.4%. Its deepest 1-year drawdown was 55.0%.

LUNG key facts

Asset type

Stock

Asset class

Equity

Inception date

10/01/2020

Distribution frequency

None

Last close

$1.78 (as of 2026-10-16)

Market cap

$76,447,919

Average volume

243987.0

Beta

0.336

Payout ratio

0.0%

Forward P/E

28.3286

EPS

$-1.15

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

LUNG risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 55.0%.

Who may consider LUNG — and who may not

It is a weaker fit for investors who need monthly cash flow (LUNG does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on LUNG

• All tickers starting with L

Tagged: Healthcare.

Frequently asked questions